

Neurotoxic snake bite with respiratory failure

Prithwis Bhattacharya, Arpan Chakraborty

Abstract

Thirteen patients with severe neuroparalytic snake envenomation admitted in intensive care unit with respiratory failure over a four months period. Initially ptosis and ophthalmoplegia, followed by bulbar palsy and respiratory muscle weakness was the common sequela. All of them received cardio-respiratory support with mechanical ventilation, anti-snake venom (median dose of 20 vials) and anticholinesterase therapy. Except one suffering from hypoxic brain injury due to delayed presentation, rest survived with complete neurological recovery. So good outcome in such cases is related with early cardio respiratory support and anti venom therapy

Key words: Anticholinesterase, envenomations, polyvalent anti-snake venom

Introduction

Snakebites remain a public health problem in many countries even though it is difficult to be precise about the actual number of cases. According to toxicity, they are categorized as hematotoxic, neurotoxic and myotoxic. Among the neurotoxic group, the majority of bites are due to *Naja naja* (common cobra), *Ophiophagus hannah* (king cobra) and *Bungarus caeruleus* (Krait) in India. The snake venom consists of different enzymatic and nonenzymatic components loosely categorized as neurotoxins and hemorrhagens. In our ICU, most of the cases admitted are neurotoxic snakebites from the above-mentioned three commonest varieties. Neurotoxic envenomations have the potency to cause a broad spectrum of presentations starting from ptosis and ophthalmoplegia to respiratory arrest. Timely administered anti-snake venom and ventilatory assistance can prevent the mortality and morbidity of the victims.^[1-5]

Case History

In our ICU, all the patients (from eastern U.P) of neurotoxic envenomation presented with neuromuscular involvement with respiratory paralysis during the period of June to September in 2005. They were received in emergency OPD where they were resuscitated and shifted to ICU as early as possible. Detailed history and systemic examination, site of bite, any local reaction at the site of bite were recorded. Routine laboratory investigations including arterial blood gases and complete hemogram with coagulation profile were sent at the time of admission. APACHE - II scoring was done for every patient at the time of admission. All the patients were ventilated [Table 1] initially in controlled mode in Datex Ohmeda Centiva-5 ventilator. With the improvement of neuromuscular paralysis, weaning was implemented through SIMV-CPAP modes. If successfully tolerated, they were put on T-piece trial. Extubation was done after assessing clinically and arterial blood gas parameters [Table 2].

From:

Department of Anesthesiology, Institute of Medical Sciences, Banaras Hindu University, Varanasi - 221 005, India

Correspondence:

Dr. Arpan Chakraborty, Department of Anesthesiology, Institute of Medical Sciences, Banaras Hindu University, Varanasi - 221 005, India.
E-mail: arpan_1977@sify.com

Polyvalent anti-snake venom (ASV) started as loading dose (50 ml over two hours) and maintenance infusion (50 ml six hourly). We have also used anticholinesterase (i.e. neostigmine started at a rate of 25 mcg/kg/hour) and anticholinergic (glycopyrolate) combination as infusion to

Table 1: Indications for mechanical ventilation

Acute ventilatory failure	pH <7.30, PaCO ₂ >50 mmHg, apnea
Impending ventilatory failure	
Tidal volume	< 3-5 ml/kg
Resp. rate and pattern	>25-30/min, labored and irregular pattern
Minute ventilation	>10 L/min
PaCO ₂ trend	Increasing to over 50 mmHg
Vital signs	Increase in heart rate and blood pressure
Severe hypoxemia	PaO ₂ - <60 mmHg at FiO ₂ - >50% or PaO ₂ - <40 mmHg at any FiO ₂
	Severe cyanosis
Prophylactic ventilatory support	To reduce pulmonary complications
	To avoid hypoxia

Table 2: Criteria for extubation

Criteria	Methods of assessment
Rapid breathing index	Respiratory rate/tidal volume in liter- <100 min/L
Blood gases	Acceptable blood gases on FiO ₂ less than 40% and spontaneous minute ventilations less than 10 L/min PaO ₂ /FiO ₂ more than 300 mmHg
Cardiopulmonary assessment	Absence of cardiopulmonary problems (e.g., CHF, pulmonary edema, pneumonia, tachycardia, arrhythmia, chest retractions, distended stomach.)

reverse the neuromuscular blockade till ptosis improved in every case.^[6] Bomb BS *et al.* in 1996 showed that anticholinesterases are the cornerstone of the neurotoxic bites, even in the absence of anti-snake venom. Outcome measure studied were survival, duration of ventilation and requirement of ASV and anticholinesterase.

Out of 13 patients [Table 3], neuromuscular symptoms started within an hour of bite in eight individuals. Except in one, site of bite has been localized from history as well

Table 3: List of the patients

Age (yrs)	Sex	Site of bite	Type of snake	Onset of symptoms	APACHE - II	Treatment started after	Total ASV received	Duration of stay in ICU
40	F	Left hand	Cobra	30 min	9	5 hours	20 vials	82 hours
30	F	Left leg	Krait	2 hours	17	7 hours	17 vials	48 hours
48	M	Left leg	?	1 hour	3	1 hour	12 vials	42 hours
8	F	Right leg	Cobra	Immediate	17	1 hour	13.5 vials	5 days
14	M	?	Cobra	Immediate	17	Immediately (Outside)	27 vials	60 hours
35	M	Right ear	?	2 hours	17	4 hours	25 vials	96 hours
20	M	Lower extremity	Krait	2 hours	17	4 hours	20 vials	4 days
20	M	Lower limb	Krait	3 hours	19	4 hours	30 vials	150 hours
10	M	Left foot	Cobra	1 hour	19	4 hours	28 vials	72 hours
38	F	Right hand	? Cobra	1 hour	17	12 hours	20 vials	88 hours
23	M	Scrotum	?	1 hour (paralysis started after 24 hours)	8	24 hours	12 vials	72 hours
45	M	Right ear	?	3 hours	5	8 hours	13 vials	35 hours
10	F	Left elbow	? Cobra	30 min	17	2.5 hours	10 vials	67 hours (till death)

APACHE II - Acute physiology and chronic health evaluation II, ICU - Intensive care unit

as bite mark. One patient has developed local cellulitis at the site of bite for which higher antibiotic coverage and low molecular weight dextran was given.

In all patients, anti-snake venom was given within a short period of the onset of symptoms and continued till significant recovery of power of all four limbs and intercostal muscles. ASV requirement was varying from 10 vials to 30 vials maximum up to 48h of bite. No patient in our series demonstrated any hypersensitivity reaction to anti snake venom. Anticholinesterase therapy continued till the improvement of the ptosis [Figure 1].

In one case that presented with cardiac arrest and was revived after prolonged CPR, the anti-snake venom could be administered only 12h after the onset of symptoms. That patient had already aspirated before being brought to the hospital. His pulmonary condition deteriorated rapidly and he finally expired.




Figure 1: Duration of neostigmine therapy in survived patients

We have started ciprofloxacin and metronidazole as an empirical basis in all the patients on admission to prevent soft tissue infection at the site of bite. Most of them recovered uneventfully. In four patients with aspiration pneumonitis we had to add/change the antibiotics according to culture-sensitivity reports from endotracheal tube specimens.

No patients presented with any bleeding episode or renal involvement or any cardiac injury. No patient needed reintubation in our series

Discussion

Ophitoxemia (clinical spectrum of venomous snake bite) starts with the onset of local changes within six to eight min of snakebite. Local pain, tenderness and reddish wheal followed by edema, swelling and appearance of bullae is a feature common to all snakes. Cobra and Kraits usually produce early wet gangrene whereas vipers produce a slower onset dry gangrene. Apart from fright and psychological shock, cobra bites can produce symptoms as early as 5 - 30 minutes or it may be delayed up to 10h. In one patient, neuromuscular symptoms started after 24h of bite. They selectively produce a flaccid type neuromuscular paralysis. Muscles innervated by cranial nerves are involved earlier. While ptosis and ophthalmoplegia are among the first symptoms (found in all cases), the pupils and diaphragm are the most resistant to toxins. But pupillary changes (found dilated in three patients) can occur earlier as a consequence of respiratory arrest and hypoxia - as was evident in our cases. Cardiotoxic features include tachycardia, hypotension and ECG changes.

Pre-synaptic as well as postsynaptic neurotoxins of cobra and krait affect mainly muscles of eye, tongue, throat and chest causing respiratory failure.^[7] Severity of envenomations and respiratory paralysis is related to dose of venom injected, potency of venom, anatomic location of bite, age, health and immune status of the victim and timely medical intervention.^[8] In all patients timely administration of ASV and cardio respiratory support was led to favorable outcome.

Immediate endotracheal intubation is necessary in patients with bulbar involvement to protect airway. Weaning from mechanical ventilation is relatively easy as the patients are otherwise healthy and usually




Figure 2: Duration of ventilatory support in survived patients

responsive to ASV within short period of time as in our study. Duration of mechanical ventilation in our patients is shown in [Figure 2].

In our study, we have used lower loading dose of ASV and maintenance infusion through syringe pump.^[9] Anticholinesterase therapy was administered to all patients to combat postsynaptic toxins as most of them reached very early (median duration of four hours) to us.

Conclusion

From our study we can conclude that administration of anti-snake venom with anticholinesterase therapy and cardio-respiratory support is the mainstay of therapy in neurotoxic envenomation with respiratory failure. Outcome is excellent if management is started early and before irreversible hypoxic insult.

References

1. Udawadia FE. Critical care in envenomation. *In: Principles of critical care.* Udawadia FE. Oxford University Press: Delhi; 1995. p. 607-11.
2. Mehta SS, Kelkar PN, Parikh NN. Respiratory failure after snake bite poisoning successfully treated with prolonged artificial ventilation. *Indian J Anaesth* 1968;16:273-5.
3. Bhatnagar NS. Artificial respiration in snake bite. *J Indian Med Assoc* 1969;52:476-8.
4. Pawar DK, Singh S. Elapid snake bite. *Br J Anaesth* 1987;59:385-7.
5. Casale FF, Patel SM. Elapid snake bite. A report of two cases. *Br J Anaesthesia* 1974;46:162.
6. Watt G, Theakston RD, Hayes CG, Yambao ML, Sangalang R, Ranoa CP, *et al.* Positive response to edrophonium in patients with neurotoxic envenoming by cobras (*Naja naja philippinensis*).

- N Engl J Med 1986;315:1444-8.
7. Mitra S. Snake bite in India and its management. J Indian Med Assoc 1987;85:129-31.
 8. Agrawal PN, Aggarwal AN, Gupta D, Behera D, Prabhakar S, Jindal SK: Management of respiratory failure in severe neuroparalytic snake envenomation. Neurol India 2001;49:25-8.
 9. Agarwal R, Aggarwal AN, Gupta D, Behera D, Jindal SK. Low dose of snake antivenom is as effective as high dose in patients with severe neurotoxic snake envenoming. Emerg Med J 2005;22:397-9.

Source of Support: Nil, **Conflict of Interest:** None declared.

This PDF is available for free download from
a site hosted by Medknow Publications
(www.medknow.com).

Author Help: Sending a revised article

- 1) Include the referees' remarks and point to point clarification to those remarks at the beginning in the revised article file itself. In addition, mark the changes as underlined or coloured text in the article. Please include in a single file
 - a. referees' comments
 - b. point to point clarifications on the comments
 - c. revised article with text highlighting the changes done
- 2) Include the original comments of the reviewers/editor with point to point reply at the beginning of the article in the 'Article File'. To ensure that the reviewer can assess the revised paper in timely fashion, please reply to the comments of the referees/editors in the following manner.
 - There is no data on follow-up of these patients.
Authors' Reply: The follow up of patients have been included in the results section [Page 3, para 2]
 - Authors should highlight the relation of complication to duration of diabetes.
Authors' Reply: The complications as seen in our study group has been included in the results section [Page 4, Table]